Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not all are so complicated. Gilead has a 1 pill a day regimen.
You would think if a Dr has a patient with resistance. to multiple drugs, then he'd encourage such a patient to try Pro140 trial. Apparently that is rarer than I'd thought.
On a per site basis, then 1 or 2 patients are enrolled per year. That's bad.
I would say not enough buying pressure. An uplist would help with that.
No, by the end Q1 in 2017. He said on Oct 11, that it would be 5 months.
I was going to complain about the lack of shares traded, but it is a Friday and it is the last trading day before Christmas, so never mind. The same would go for the entire week between Christmas and New Years.
My real concern is a low buyout. The only way there is no buyout would be if there's a dramatic SAE, God forbid. And there's no sign of that in previous trials.
I agree, but some of that would be in the form of warrants. Most of CYDY's warrants have yet to be cashed in. Last year I would have presumed they would all be well in the money by now.
I don't think the market discounts the value of the adjunct therapy, but perhaps they are totally oblivious and / or dismissive to CYDY. Their logic might be since they have only 4 employees, their value should be zero.
A 10-bagger from combo efficacy alone ? And you expect 1,000% in less than 3 months ? Or more like 3 trading days after the announcement. I agree that is what should happen, but we shouldn't be sub-dollar now. IMO, We'd need to see a 10 million share day, with regular million plus days, not 10 thousand share days.
Nader said that Adjunct was also a multi-billion $ market. So you disagree with that, or would adjunct not command the price to sales ratio ?
All the more reason to get off the }%~|{]#<>% bulletin boards. If the share price is knocked down then I will buy the whole company for a nickel. ??. On a major exchange, the shorts may be 5 times bigger, but the longs are 100 times bigger. Plus, and this is the thing that REALLY gives them chills ... is they HAVE to cover before the change over. Squeeze.
What would push Cydy to $6 besides approval ?
Volume of 2K shares at noon. Sad to say, my paycheck could purchase that much ! No interest in the stock because of the holidays and otc. Anonymity continues.
But is that low volume a result of the company's prospects, or the result of not being on NASDAQ (or NYSE). Isn't there a Catch 22 going on ? Can't get volume until you uplist, can't uplist until the share price goes up, price can't go up until you have volume, and the cycle goes on.
Nader' refusal to uplist grows more suspect in my mind. I have entertained the thought that some deal has been worked out and that he wants to keep CYDY as ... inaccessible (?) as he can so that the acquirers won't have to pay more than what was already agreed to privately. I don't actually believe that, but that's a thought which is getting tougher to refute. As Goldmember would say, "Ishn't that veird?"
Very good, thank you.
No, only until then. After, hopefully the sky's the limit.
Then why ....? Unless prospective phase 3 patients can see this to encourage them to enroll in the trial.
I imagine permission was given by patients at the time of recording, which was early October or earlier. Unless the the FDA has a say in this, it's pointless to keep this under wraps. Editing and production shouldn't take that long.
The market seems to be totally disbelieving or oblivious to Cydy. Volume is frequently less than 100 k. No shares can be traded for 2 hours. Don't think the price will move until serious money comes in. Even with efficacy, I now doubt the market will take notice. Markets can be stupid. Remember the internet boom ? That was stupid. I'm not guaranteeing they will continue in stupidity, but there is no clue that they will.
Who has seen this video ? When is Cydy planning to show it to somebody ? Why wait ?
The. Volume is so low that shorts can almost always hold it down. Catch 22. Can't uplist until the price goes up, price can't go up until the volume increases, volume won't increase until we uplist. At FDA approval, CYDY could still be otc. Not likely, but possible.
You're right sorry
Yes, sorry.
Nader now expects Mono efficacy results by end of Q1. Some here (not me) expect it earlier. If enrollment in mono is very quick, then it would be. I like to keep expectations low to not be disappointed and "keep an even keel". Because delays happen.
Ok, NNW Headlines is where to click.
Great ! However, The NNW website doesn't have anything about CYDY that I saw. Will this be posted later today or tomorrow ? Or was I looking in the wrong page ?
test
We're back on ! After an exciting day a 34,000 shares traded.
Markets are frequently irrational
Without progress through trials, a pre revenue bio is worth ZERO.
The measure for Cydy now is not share price, but progress through the trials. In that regard it he is doing fairly well. Could be better, but good. We are months away from finishing two phase 3's and FDA has made some concessions. I feel good about management. I would very much like more info on the slowness of the combo trial.
That's a good justification for a possible expected buyout price. But wouldn't the new indications for cancer, lupus etc bring that up a bit ? Or isn't there enough time to move them far enough in trials to make a difference ?
A lot of new names here on the board, welcome !
Why would that be ? What is so different between the two phases ?
But what is the price where 51% of shareholders say, ok ? That price now might be less than $1B, imo. If pharma were only slightly gutsy, they'd make a lower offer now and steal CYDY.
...can anyone narrow the range of current patient numbers better than 2 and 29 ?
Well...with 4 employees what do you expect ? Then again, I'd expect them to hire just a couple more people to do things like that for instance. On the third hand, Part of the reason that they've hung around and with less dilution is that they're so small. It's a hard knock life.
How long will it be before an SA author writes an article on CYDY, and not just a brief mention ?